Literature DB >> 281967

Surface antigens in acute myeloblastic leukaemia: a study using heterologous antisera.

L Tupchong, I C MacLennan.   

Abstract

This study analyses the activity of 95 antisera raised in rabbits against human leukaemic myeloblasts. A number of different means were used to immunize both normal rabbits and rabbits which had been treated to render them tolerant of normal human splenic leucocytes. Different immunization schedules included the use of different doses of untreated myeloblasts, as well as myeloblasts treated with neuraminidase, antibody against human spleen cells or glutaraldehyde. Analysis of the sera was carried out using two sensitive techniques for detecting cell surface antigens: a radioactive anti-immunoglobulin binding assay using 125I-horse-F(ab')2-anti-rabbit-Fab and a K-cell-mediated cytotoxicity test using rat spleen cells as effectors. (i) The unabsorbed sera showed similar mean titres against leukaemic myeloblasts and normal splenocytes. (ii) Extensive absorption with pooled cadaveric spleen were required to remove antibody against polymorphic antigens. (iii) 17/95 antisera had activity against at least some leukaemic myeloblasts after extensive absorption with cadaveric spleen. (iv) Some of the 17 absorbed sera with selective activity for myeloblasts also reacted against PHA-induced lymphoblasts. (v) Although the 17 absorbed sera showed little or no activity against marrow in the above assays normal human marrow totally absorbed all residual activity in these sera against leukaemic myeloblasts. We conclude that although these sera contain activity against antigens common to leukaemic myeloblasts and a minority population of normal marrow cells, they have no detectable activity against leukaemic-specific antigens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 281967      PMCID: PMC2009758          DOI: 10.1038/bjc.1978.235

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  HL-A antibody response in patients with acute myelogenous leukaemia treated by immunotherapy.

Authors:  T P Klouda; S D Lawler; R L Powles; R T Oliver; C K Grant
Journal:  Transplantation       Date:  1975-03       Impact factor: 4.939

Review 2.  Clinical applications of cell surface markers.

Authors:  M F Greaves
Journal:  Prog Hematol       Date:  1975

3.  Antibody in the induction and inhibition of lymphocyte cytotoxicity.

Authors:  I C MacLennan
Journal:  Transplant Rev       Date:  1972

4.  Leukaemia-associated antigens in man. Detection by antibodies in maternal sera.

Authors:  P R Cullen; D Y Mason
Journal:  Clin Exp Immunol       Date:  1974-08       Impact factor: 4.330

5.  Delayed cutaneous hypersensitivity in leukaemic patients to autologous blast cells.

Authors:  M A Baker; R N Taub; S M Brown; K Ramachandar
Journal:  Br J Haematol       Date:  1974-08       Impact factor: 6.998

6.  Human lymphocyte alloantigen(s) similar to murine Ir region-associated (Ia) antigens.

Authors:  R D Arbeit; D H Sachs; D B Amos; H B Dickler
Journal:  J Immunol       Date:  1975-10       Impact factor: 5.422

7.  Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.

Authors:  C B Freeman; R Harris; C G Geary; M J Leyland; J E MaCiver; I W Delamore
Journal:  Br Med J       Date:  1973-12-08

8.  The occurrence of the HL-B alloantigens on the cells of unclassified acute lymphoblastic leukemias.

Authors:  S M Fu; R J Winchester; H G Kunkel
Journal:  J Exp Med       Date:  1975-11-01       Impact factor: 14.307

9.  Autologous stimulation of human lymphocyte subpopulation.

Authors:  G Opelz; M Kiuchi; M Takasugi; P I Terasaki
Journal:  J Exp Med       Date:  1975-11-01       Impact factor: 14.307

10.  Lymphocyte transformation induced by autologous cells. IV. Human T-lymphocyte proliferation induced by autologous or allogeneic non-T lymphocytes.

Authors:  M M Kuntz; J B Innes; M E Weksler
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.